Supplemental Figure 1. Copy number alterations of AAPC exome set. Supplemental Figure 2. Copy number analysis grouped by Gleason scores. Supplemental Figure 3. Recurrent somatic copy number alterations in the AAPC cohort. Supplemental Figure 4. Analysis of fraction of copy number altered genome in the AAPC exome and TCGA cohorts. Supplemental Figure 5. Prostatic adenocarcinomas with unique ERF mutations demonstrate decreased RNA expression by RNA ISH. Supplemental Figure 6. IGV screenshots of validated ERF mutations. Supplemental Figure 7. Frequencies of mutations in ERF across several published prostate cancer sequencing cohorts. Supplemental Figure 8. Visualization of deletions at chr19q13.2 in the TCGA cohort and analysis of SU2C/CRPC dataset for ERF mutations. Supplemental Figure 9. Association ERF deletion status with pathologic features. Supplemental Figure 10. Knockdown of ERF mRNA in prostate cancer cell lines and an immortalized prostate epithelial cell line. Supplemental Figure 11. Knockdown of ERF in PC�3 cell line augments invasion and tumor xenograft growth. Supplemental Figure 12. Overexpression of ERF in PC�3 cell line is associated with a growth inhibitory effect. Supplemental Figure 13. Knockdown of ERF in RWPE�1 and LNCaP cell lines contributes to growth proliferation. Supplemental Figure 14. Overexpression of ERF in DU�145 cell line. Supplemental Figure 15. Association of LHS�AR ERF KD signature in the CCLE and CRPC datasets. Supplemental Figure 16. ERF mutation and deletions are mutually exclusive from ERG rearrangement events in the published TCGA cohort (n=333) (cbioportal.org). Supplemental Figure 17. ERF KD signature in setting of ERF overexpression and correlation with Gleason score. Supplemental Figure 18. Association of LHS�AR ERF KD signature projected across the CCLE. Supplemental Figure 19. Mutation plot of combined AAPC (n=102) + TCGA (n=457) analysis. Supplemental Figure 20. ERF nucleotide sequence map.